Suchergebnisse - "Todd M. Bauer"

1

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

von: Jennifer Brown

2017, in: Experimental Hematology & Oncology

Wird geladen...
2

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

von: Christian U. Blank

2021, in: Current Oncology

Wird geladen...
3

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

von: Jennifer Mataraza

2020, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
4

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

von: Asim Amin

2018, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
5

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

von: Asim Amin

2019, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
6

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

von: Thomas Yau

2023, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
7

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

von: Rui Wang

2022, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
8

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

von: D. Ross Camidge, MD, PhD

2022, in: JTO Clinical and Research Reports

Wird geladen...
9

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

von: Stephane Champiat

2023, in: Journal for ImmunoTherapy of Cancer

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!